The Europe cancer biomarker market is poised to grow at a CAGR of 10.83% for the years 2019-2027. Technological progress in research and developmental activities has progressed the growth of the cancer biomarker market in Europe.
The European market has a huge opportunity to grow in personalized medication on account of the support generated for the biomarkers test, growing medical tourism and the rising number of cancer patients in the region. Also, the various market segments and sub-segments with respect to biomarkers, application, cancer type and profiling technology are proving to be quite profitable for the market growth during the forecast period. However, the lack of acceptance of the cancer biomarker from the general populace, unfavorable compensation and the shortage of skilled personnel are some of the major challenges faced by the market in the region.
Some of the leading players in the market are Agendia N.V., Becton Dickinson and Company, Qiagen N.V., Diadexus Inc. (Acquired By Diazyme Laboratories), Aureon Biosciences, Inc., Agilent Technologies, Inc., Clarient, Inc. (Acquired By Neogenomics Laboratories), Astellas Pharma Inc., Beckman Coulter, Sanofi, Bristol-Myers Squibb, Abbott Laboratories, Roche Diagnostics Ltd., Illumina, Inc. and Celgene Corporation.